CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (65,761)	$ (199,228)	$ (2,483)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	172,223	155,538	99,886
Impairment of intangible assets	0	319,246	19,663
Provision for bad debt expense	678	3,852	3,209
Amortization of premium/discount on purchased securities	87	302	624
(Gain) loss on disposal of fixed assets	(99)	265	0
Non-cash equity-based compensation expense	19,916	23,664	22,543
Non-cash IPR&D expense	0	945	0
Loss on debt extinguishment	35,922	10,926	0
Amortization of debt discount and debt issuance costs	15,658	14,395	12,105
(Gain) loss on sale of investments, net	(1)	70	38
Change in fair value of contingent consideration	(49,607)	(47,686)	25,683
Deferred income taxes	41,166	(178,421)	7,279
Gain on sale of the CBR business	(87,076)	0	0
Transaction costs	(14,111)	0	0
Changes in operating assets and liabilities:
Accounts receivable, net	16,995	(14,978)	(9,906)
Inventories	4,722	(2,331)	(2,355)
Receivable from collaboration	0	0	428
Prepaid and other current assets	(6,097)	(2,222)	4,095
Accounts payable and accrued expenses	(32,568)	16,834	49,037
Deferred revenues	8,658	17,080	24,522
Payment of contingent consideration in excess of acquisition date fair value	0	(10,432)	(8,116)
Other assets and liabilities	95	(1,223)	(30)
Net cash provided by operating activities	60,800	106,596	246,222
Cash flows from investing activities:
Proceeds from sales or maturities of marketable securities	85,342	294,957	127,479
Purchase of marketable securities	(89,956)	(127,249)	(194,723)
Acquisition of Intrarosa intangible asset	0	(55,800)	0
Proceeds from the sale of the CBR business	519,303	0	0
Note receivable	(10,000)
Note receivable		0	0
Capital expenditures	(2,534)	(8,988)	(5,460)
Net cash provided by (used in) investing activities	502,155	102,920	(72,704)
Cash flows from financing activities:
Long-term debt principal payments	(475,000)	(353,125)	(17,502)
Proceeds from 2022 Convertible Notes	0	320,000	0
Payments to repurchase 2019 Convertible Notes	0	(191,730)	0
Payment of premium on debt extinguishment	(28,054)	(625)	0
Proceeds to settle warrants	0	323	0
Payment of convertible debt issuance costs	0	(9,553)	0
Payment of contingent consideration	(119)	(39,793)	(92,130)
Payments for repurchases of common stock	0	(19,466)	(20,000)
Proceeds from the exercise of common stock options	3,881	3,021	3,885
Payments of employee tax withholding related to equity-based compensation	(2,682)	(2,696)	(2,171)
Net cash used in financing activities	(501,974)	(293,644)	(127,918)
Net increase (decrease) in cash, cash equivalents and restricted cash	60,981	(84,128)	45,600
Cash, cash equivalents and restricted cash at beginning of the year	192,770	276,898	231,298
Cash, cash equivalents and restricted cash at end of the year	253,751	192,770	276,898
Supplemental data of cash flow information:
Cash paid for taxes	5,345	5,296	5,309
Cash paid for interest	48,757	56,959	62,381
Non-cash investing and financing activities:
Fair value of common stock issued in connection with the acquisition of the Intrarosa intangible asset		13,500
Endoceutics, Inc.
Non-cash investing and financing activities:
Fair value of common stock issued in connection with the acquisition of the Intrarosa intangible asset	0	12,555	0
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset	$ 0	$ 9,300	$ 0